Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects

• Published in: Stroke (1970) Vol. 38; no. 3; pp. 1036 - 1043
• Main Authors: LOPEZ-ATALAYA, Jose P, ROUSSEL, Benoit D, ALI, Carine, MAUBERT, Eric, PETERSEN, Karl-Uwe, BEREZOWSKI, Vincent, ROMEO, Cecchelli, ORSET, Cyrille, VIVIEN, Denis
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 01.03.2007; American Heart Association
• Subjects: Animals; Biochemistry, Molecular Biology; Biological and medical sciences; Blood-Brain Barrier - drug effects; Blood-Brain Barrier - metabolism; Blood. Blood coagulation. Reticuloendothelial system; Cattle; Cells, Cultured; Chiroptera; Coculture Techniques; Desmodus rotundus; Fibrinolytic Agents - pharmacokinetics; Fibrinolytic Agents - toxicity; Humans; Life Sciences; Low Density Lipoprotein Receptor-Related Protein-1 - physiology; Male; Medical sciences; Neurology; Neuropharmacology; Neuroprotective agent; Pharmacology. Drug treatments; Plasminogen Activators - pharmacokinetics; Plasminogen Activators - toxicity; Rats; Rats, Sprague-Dawley; Recombinant Proteins - pharmacokinetics; Recombinant Proteins - toxicity; Vascular diseases and vascular malformations of the nervous system; Vascular disease; Stroke; Nervous system diseases; Toxicity; Desmoteplase; Excitotoxicity; blood-brain barrier ■ desmoteplase ■ excitotoxicity ■ stroke ■ thrombolysis; Central nervous system disease; Cardiovascular disease; Blood brain barrier; Cerebrovascular disease; Cerebral disorder; Blood-brain barrier; Thrombolysis

Desmoteplase, a recombinant form of the plasminogen activator DSPAalpha1 from Desmodus rotundus, may offer improved clinical benefits for acute ischemic stroke treatment over the current therapy, recombinant tissue plasminogen activator (rtPA). Accumulating evidence suggests that clinical use of rtP...